IL-33, as a candidate for cytokine therapies, can effectively enhance Sema4A expression and stimulate anti-tumoral cells including NK and CD8+ T cells (29, 94), while the mechanism of IL-33 on anti-tumor effects remains unclear. The gene discussed is IL33; the disease is neoplasm.